Patent application number | Description | Published |
20090104232 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST YERSINIA PESTIS - The invention provides a gene transfer vector for inducing an immune response against | 04-23-2009 |
20100119474 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE SUSCEPTIBILITY AND RELATED COMPOSITIONS AND METHODS - The invention provides a method of determining the likelihood that a smoker will or will not develop chronic obstructive pulmonary disease (COPD) by obtaining a sample from the smoker, analyzing the sample for the expression of a set of biomarkers associated with COPD, and comparing the expression pattern determined in the sample with a standard expression pattern to determine the likelihood that the smoker will or will not develop COPD. The invention further provides a composition, a method of treatment, and methods of determining the efficacy of treatment for COPD. | 05-13-2010 |
20110086063 | VACCINES FOR PREVENTION AND TREATMENT OF ADDICTION - The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody directed against the addictive drug. The invention further provides a method of inducing an immune response against an addictive drug or reducing the effect of an addictive drug in a human by ad-ministering to the human the aforementioned adenovirus-antigen conjugate or antibody encoding adenoviral vector. | 04-14-2011 |
20130090375 | VIRUS-MEDIATED DELIVERY OF BEVACIZUMAB FOR THERAPEUTIC APPLICATIONS - The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal. | 04-11-2013 |
20140073519 | LUNG CANCER-RELEVANT HUMAN EMBRYONIC STEM CELL SIGNATURE - The invention provides a method of detecting cancer, a progression of cancer, or a predisposition to cancer in a human, comprising (a) obtaining a sample of airway basal cells from the human, and (b) analyzing the sample to determine expression of one or more hESC-signature genes, wherein the expression or lack of expression of the one or more hESC-signature genes is indicative of a presence or absence of cancer, a progression of cancer, or a predisposition to cancer in the human. The invention also provides an in vitro model for lung cancer, comprising airway basal cells that express one or more hESC-signature genes. | 03-13-2014 |
20140221462 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CARDIOMYOPATHY DUE TO FRIEDREICH ATAXIA - A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN). | 08-07-2014 |
20150056251 | AAV-DIRECTED PERSISTENT EXPRESSION OF AN ANTI-NICOTINE ANTIBODY GENE FOR SMOKING CESSATION - The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody that binds to nicotine or a nicotine analog, or an antigen-binding fragment thereof. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal. | 02-26-2015 |